Search research articles
Contact Us
Filters
Showing results (111-120 of 184) with videos related to
Page
of 19
Sort By:
Investigational New Drugs
|
October 7, 2006
Cytotoxic activity of Apomine is due to a novel membrane-mediated cytolytic mechanism independent of apoptosis in the A375 human melanoma cell line
Alan Pourpak, Robert T Dorr, Ross O Meyers, et al.
Cancer Treatment Reports
|
February 1, 1979
Limitations of a portable infusion pump in ambulatory patients receiving continuous infusions of anticancer drugs
R T Dorr, C E Trinca, K Griffith, et al.
Cancer Chemotherapy and Pharmacology
|
March 27, 2010
Imexon enhances gemcitabine cytotoxicity by inhibition of ribonucleotide reductase
Nicholas O Roman, Betty K Samulitis, Lee Wisner, et al.
Cancer Chemotherapy and Pharmacology
|
December 22, 2011
Anti-tumor activity and mechanism of action for a cyanoaziridine-derivative, AMP423
Robert T Dorr, Lee Wisner, Betty K Samulitis, et al.
Pharmaceutical Research
|
July 11, 2000
Pharmacologic response of a controlled-release PLGA formulation for the alpha-melanocyte stimulating hormone analog, Melanotan-I
R Bhardwaj, M E Hadley, R T Dorr, et al.
Translational Oncology
|
June 29, 2012
Tumor Xenograft Response to Redox-Active Therapies Assessed by Magnetic Resonance Imaging Using a Thiol-Bearing DOTA Complex of Gadolinium
Gerald P Guntle, Bhumasamudram Jagadish, Eugene A Mash, et al.
Cancer Research
|
May 4, 2005
Mitochondrial-mediated disregulation of Ca2+ is a critical determinant of Velcade (PS-341/bortezomib) cytotoxicity in myeloma cell lines
Terry H Landowski, Christina J Megli, Kevin D Nullmeyer, et al.
Cancer
|
December 15, 1989
High levels of doxorubicin in the tissues of a patient experiencing extravasation during a 4-day infusion
R T Dorr, M S Dordal, L M Koenig, et al.
Journal of Medicinal Chemistry
|
December 6, 1996
2-[2'-(Dimethylamino)ethyl]-1,2-dihydro- 3H-dibenz[de,h]isoquinoline-1,3-diones with substituents at positions 4, 8, 9, 10, and 11. Synthesis, antitumor activity, and quantitative structure-activity relationships
S M Sami, R T Dorr, D S Alberts, et al.
Cancer Treatment Reports
|
July 1, 1985
Methotrexate: bioavailability and pharmacokinetics
M A Campbell, D G Perrier, R T Dorr, et al.
Page
of 19
Search research articles
Search
Showing results (111-120 of 184) with videos related to
Sort By:
Page
of 19
Investigational New Drugs
|
October 7, 2006
Cytotoxic activity of Apomine is due to a novel membrane-mediated cytolytic mechanism independent of apoptosis in the A375 human melanoma cell line
Alan Pourpak, Robert T Dorr, Ross O Meyers, et al.
Cancer Treatment Reports
|
February 1, 1979
Limitations of a portable infusion pump in ambulatory patients receiving continuous infusions of anticancer drugs
R T Dorr, C E Trinca, K Griffith, et al.
Cancer Chemotherapy and Pharmacology
|
March 27, 2010
Imexon enhances gemcitabine cytotoxicity by inhibition of ribonucleotide reductase
Nicholas O Roman, Betty K Samulitis, Lee Wisner, et al.
Cancer Chemotherapy and Pharmacology
|
December 22, 2011
Anti-tumor activity and mechanism of action for a cyanoaziridine-derivative, AMP423
Robert T Dorr, Lee Wisner, Betty K Samulitis, et al.
Pharmaceutical Research
|
July 11, 2000
Pharmacologic response of a controlled-release PLGA formulation for the alpha-melanocyte stimulating hormone analog, Melanotan-I
R Bhardwaj, M E Hadley, R T Dorr, et al.
Translational Oncology
|
June 29, 2012
Tumor Xenograft Response to Redox-Active Therapies Assessed by Magnetic Resonance Imaging Using a Thiol-Bearing DOTA Complex of Gadolinium
Gerald P Guntle, Bhumasamudram Jagadish, Eugene A Mash, et al.
Cancer Research
|
May 4, 2005
Mitochondrial-mediated disregulation of Ca2+ is a critical determinant of Velcade (PS-341/bortezomib) cytotoxicity in myeloma cell lines
Terry H Landowski, Christina J Megli, Kevin D Nullmeyer, et al.
Cancer
|
December 15, 1989
High levels of doxorubicin in the tissues of a patient experiencing extravasation during a 4-day infusion
R T Dorr, M S Dordal, L M Koenig, et al.
Journal of Medicinal Chemistry
|
December 6, 1996
2-[2'-(Dimethylamino)ethyl]-1,2-dihydro- 3H-dibenz[de,h]isoquinoline-1,3-diones with substituents at positions 4, 8, 9, 10, and 11. Synthesis, antitumor activity, and quantitative structure-activity relationships
S M Sami, R T Dorr, D S Alberts, et al.
Cancer Treatment Reports
|
July 1, 1985
Methotrexate: bioavailability and pharmacokinetics
M A Campbell, D G Perrier, R T Dorr, et al.
Page
of 19